HCP Action Required: Complete NEXPLANON REMS Certification by August 23, 2026 to Maintain Access to NEXPLANON® (etonogestrel implant) 68 mg

August 4, 2026 12:00 am EDT All healthcare providers who dispense NEXPLANON® (etonogestrel implant) 68 mg are required to complete NEXPLANON REMS certification by August 23, 2026 to maintain access to NEXPLANON. All providers who administer NEXPLANON must become REMS certified, including those who previously completed the Clinical Training Program (CTP). The goal of the NEXPLANON REMS is to mitigate complications due to improper insertion and removal. Certification requirements vary by provider status: Active inserters: Complete certification online at www.NEXPLANONREMS.com by reviewing the Prescribing Information and Healthcare Provider Guide and submitting the Knowledge Assessment and Enrollment Form. Inactive or new providers: Complete all required training, including online didactic and in-person practical training. Providers are encouraged to begin the certification process as soon as possible to allow sufficient time before the deadline. For questions about REMS certification, contact the NEXPLANON REMS Program at 1-833-NXP-REMS (1-833-697-7367) or Organon at 1-844-674-3200. Before prescribing NEXPLANON, please read the Prescribing Information, including Boxed Warning. The Patient Information also is available. Opens a new window Opens a new window Opens a new window Opens a new window Opens a new window Company About us Our Leaders Environmental, social & governance Policies & positions Resources Patient resources Investor relations Media Organon Pro for healthcare professionals Contact us Contact information Global locations Forward-Looking Statement Cookie policy Privacy Policy Consumer Health Data Policy Terms of Use Sitemap © 2026 Organon group of companies. All rights reserved. ORGANON and the ORGANON Logo are trademarks of the Organon group of companies. This site is intended for residents of the United States. Opens a new window Opens a new window You are leaving Organon.com Cancel Continue Opens a new window Forward-looking statement of Organon Any statements set forth on this website that are not historical facts are considered “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Organon’s management and are subject to significant risks and uncertainties. By their nature, forward-looking statements involve risks and uncertainties because they depend on circumstances that may or may not occur in the future. Although these statements are based on assumptions that we believe are reasonable when made, we caution you that forward-looking statements are not guarantees of future performance and you should not place undue reliance on them. Organon undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s other filings with the Securities and Exchange Commission (SEC), including its registration statement on Form 10, available at the SEC’s Internet site (www.sec.gov). Decline Accept

The release as fetched from its publisher. organon.com ↗